liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function
Department of Gastroenterology, Skåne University Hospital, Lund, Sweden.
Linköping University, Department of Medical and Health Sciences, Clinical Pharmacology. Linköping University, Faculty of Health Sciences.ORCID iD: 0000-0002-2809-7591
2012 (English)In: Journal of Crohn's and Colitis, ISSN 1873-9946, Vol. 6, no 6, 655-659 p.Article in journal (Refereed) Published
Abstract [en]

Background and aims

A pre-treatment determination of the thiopurine S-methyltransferase (TPMT) genotype or phenotype can identify patients at risk of developing severe adverse reactions from thiopurine treatment. The risk of misclassifying a patient might be dependent on the method used. The aim of this study was to investigate the concordance between TPMT genotyping and phenotyping.


The data consist of 7195 unselected and consecutive TPMT genotype and phenotype determinations sent to the division of Clinical Pharmacology, Linköping, Sweden. TPMT activity was measured in red blood cells (RBC) and the genotype determined by pyrosequencing for the three most common TPMT variants (TPMT *2, *3A, *3C).


TPMT genotyping identified 89% as TPMT wild type (*1/*1), 10% as TPMT heterozygous and 0.5% as TMPT defective. The overall concordance between genotyping and phenotyping was 95%, while it was 96% among IBD patients (n = 4024). Genotyping would have misclassified 8% of the TPMT defectives as heterozygous as compared to 11% if only TPMT activity had been measured. 11% of the heterozygous patients had a normal TPMT activity (> 8.9 U/ml RBC) and 3% of the TPMT wild-type patients had an intermediate TPMT activity (2.5–8.9 U/ml RBC).


There is a risk for TPMT misclassification when only genotyping or phenotyping is used, but it is not reasonable to check both in all patients. Since TPMT genotyping is the more reliable test, especially in TPMT heterozygotes, we suggest that genotyping should be considered the primary choice for the pre-treatment evaluation of TPMT function before initiation of thiopurine therapy.

Place, publisher, year, edition, pages
Elsevier, 2012. Vol. 6, no 6, 655-659 p.
Keyword [en]
Thiopurine methyltransferase, Thiopurines, Inflammatory bowel diseases, Genotype, Phenotype
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-79120DOI: 10.1016/j.crohns.2011.11.014ISI: 000305874000003OAI: diva2:538370
Available from: 2012-06-29 Created: 2012-06-29 Last updated: 2013-09-03

Open Access in DiVA

fulltext(217 kB)508 downloads
File information
File name FULLTEXT01.pdfFile size 217 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Lindqvist Appell, Malin
By organisation
Clinical PharmacologyFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 508 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 78 hits
ReferencesLink to record
Permanent link

Direct link